Novavax Inc. | Mutual Funds
Mutual Funds that own Novavax Inc.
SPDR S&P Biotech ETF
17,380,718
4.54%
44,715
0.46%
09/06/2018
Vanguard Total Stock Market Index Fund
9,290,836
2.43%
0
0%
07/31/2018
BB Biotech AG
8,330,000
2.18%
0
0.31%
03/31/2018
iShares Russell 2000 ETF
7,978,698
2.09%
-4,260
0.03%
09/06/2018
Vanguard Extended Market Index Fund
5,052,410
1.32%
71,020
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
4,401,064
1.14%
-57,540
0.07%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
3,429,265
0.9%
0
0.23%
06/30/2018
Fidelity Select Biotechnology Portfolio
3,364,321
0.88%
0
0.06%
07/31/2018
Franklin Biotechnology Discovery Fund
2,282,500
0.6%
2,282,500
0.24%
03/31/2018
iShares Russell 2000 Value ETF
2,257,666
0.59%
0
0.03%
09/06/2018
| Address |
20 Firstfield Road
Gaithersburg Maryland 20878
United States
|
|
Employees
|
- |
| Website |
http://www.novavax.com |
| Updated |
09/14/2018 |
| Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus. The company was founded in 1987 and is headquartered in Gaithersburg, MD. |
